Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: lexi2004 who wrote (56636)	11/8/2006 8:30:44 AM
From: hotlinktuna	Read Replies (1) \| Respond to of 59879

BSM 4.76 out w/encouraging results on breast cancer study: Use of Hyperthermia Therapy in Treating Primary and Recurrent Breast Cancer Highlights Breast Cancer Congress Wednesday November 8, 8:03 am ET SALT LAKE CITY, Nov. 8 /PRNewswire-FirstCall/ -- BSD Medical Corp. (Amex: BSM - News) today announced that breakthrough uses of hyperthermia therapy in treating both recurrent and primary breast cancer drew much attention and was a major highlight at the twelfth annual Puerto Rico Breast Cancer Conference held in conjunction with the American Cancer Society October 27-29 in San Juan. BSD Medical was a sponsor of the conference, along with co-sponsors including Bristol Myers Squibb, Pfizer, Johnson & Johnson, Merck and Abbott. The congress faculty represented opinion leaders from major universities and cancer research organizations. ADVERTISEMENT Dr. Ellen Jones of the Comprehensive Cancer Center at Duke University presented the results of two clinical studies using hyperthermia therapy, with the objective of providing better options for breast cancer patients. The first study involving 109 patients has concluded, and offers a very significant new option for women whose breast cancer has recurred in the chest wall, through a second course of radiation coupled with hyperthermia therapy. A second study that will also involve 109 patients with previously untreated advanced breast cancer is underway, with 44 patients thus far accrued and evaluated. The objective of this study is to provide a means for more women with advanced primary breast cancer to avoid surgical breast removal, or to otherwise improve their prognosis to more favorable options. Dr. Jones is a researcher in women's cancers, and her research relating to the use of hyperthermia therapy in treating breast cancer has been well published. She and fellow-researchers at Duke University authored a landmark report published May 2005 in the Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology (ASCO), showing a striking improvement in tumor response for patients with post-mastectomy chest wall recurrence, when hyperthermia therapy is added to conventional radiation therapy. Randomized previously irradiated patients who received hyperthermia therapy along with a second course of radiation experienced a complete response (total disappearance of the tumor) at a rate nearly three times higher (68.2%) than those patients who received the second radiation treatments alone (23.5%). The Duke researchers contend their findings demonstrate that hyperthermia plus radiation should be the new standard of care for these women. Dr. Jones also presented preliminary findings for the second clinical trial currently underway at Duke involving hyperthermia to treat 109 locally advanced stage IIB or IIIA/B previously untreated breast cancer patients. Forty-four patients have thus far been evaluated after treatment with a combination of chemotherapy (Paclitaxel and Evocet) and hyperthermia therapy. The hyperthermia treatments were given immediately following the administration of Evocet and were administered with each chemotherapy cycle. The patients were median age 50, and the median tumor size was 5.65 centimeters. The condition of the patients before treatment was as follows: 14 of the 44 had inflammatory breast disease, 19 of the 44 were deemed inoperable even for mastectomy and only 5 of the 44 were considered eligible for breast conservation surgery. The after-treatment results are as follows: patients deemed eligible for breast conservation surgery increased from 5 to 16, 12 of the 44 had a complete pathological response and 20 of the 44 had a partial response. Except for some minor skin irritation, side effects were similar to treatment with chemotherapy alone. Dr. Jones received her MD and PhD from Dartmouth College, was an intern at Boston's Beth Israel Hospital and completed her residency in Radiation Oncology at the Harvard Joint Center for Radiation Therapy. She was on the faculty at Harvard Medical School in Radiation Oncology at Brigham and Women's Hospital before joining the Duke University faculty in 1998. She is the Clinical Director of an NCI program project grant studying hyperthermia and perfusion effects in cancer therapy. BSD Medical develops cancer therapy systems that employ precision-guided RF/microwave energy to deliver therapeutic heat (including hyperthermia therapy) into tumors to kill cancer cells directly and make radiation and/or chemotherapy more effective. For further information about BSD Medical and its technologies visit the BSD websites at www.BSDMedical.com, www.treatwithheat.com or www.heatcancer.com. Statements contained in this press release that are not historical facts are forward-looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements and projections or expectations of future events, including the prospects for future sales of the Company's cancer therapy systems based on the success of any particular presentation of its products or its therapies, are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. -------------------------------------------------------------------------------- Source: BSD Medical Corp.

To: lexi2004 who wrote (56636)	11/8/2006 12:26:58 PM
From: lexi2004	Read Replies (1) \| Respond to of 59879

Jim, Posted to Tuna on another board to watch DSTI which has been badly beaten down and is showing improvement today, even though on low volume. Stock has a 6m float so can be a runner. While looking for news on DSTI, found this and while it's not current, think it might have meaning especially in light of election results: SENATOR CLINTON VISITS DAYSTAR TECHNOLOGIES, PROMOTES SOLAR CELL TECHNOLOGY DEVELOPMENT IN CAPITAL REGION Discusses Policy Proposals for Increasing Use of Renewable Energy Technologies Halfmoon, NY – (PR Newswire) – July 31, 2006 – DayStar Technologies, Inc. (NASDAQ:DSTI), a developer and manufacturer of innovative Photovoltaic Foil™ products, proudly welcomed Senator Hillary Rodham Clinton for a visit to its facility in Halfmoon, New York on July 29, 2006. The Senator met with executive staff and talked with numerous employees while viewing the operations of the factory. Following a brief presentation by Dr. John R. Tuttle, DayStar’s Chairman and CEO, Senator Clinton spoke to over one hundred fifty of DayStar’s employees, friends and family, gathered for an outdoor event as part of the Company’s Employee Appreciation Week. The Senator presented her policy proposals for increasing the use of renewable energies, and acknowledged DayStar’s vision in the development and manufacturing of their new and advanced solar cell technology. The Senator stated following the visit, “Everywhere I go, I hear concerns about energy prices. On Monday, the Department of Energy announced that the average price for regular gasoline in New York State had hit a new record of $3.13 a gallon. At those prices, New Yorkers will pay nearly $9 billion more for gasoline this year than they did in 2001,” Senator Clinton said. “We need to transform the way that we produce and use energy—away from foreign sources of energy like oil, and towards domestic renewable energy like solar. What DayStar is doing here in New York is a perfect example of innovation that is good for the environment and the local economy. DayStar is creating cutting-edge solar technology, with a goal of mass-producing highly affordable solar energy. I am pleased to support companies like DayStar because I believe that if we put the right policies in place, and harness the power of American innovation, we can create clean energy technologies, create jobs, and export those technologies around the world.” Senator Clinton has proposed legislation that would eliminate tax breaks for oil companies and assess a temporary fee on the profits of oil companies that do not choose to invest in renewable energy. Those resources would be put into a “strategic energy fund,” that would be dedicated to research, development and deployment of clean energy technologies. One purpose of the Strategic Energy Fund would be to create a five-year, $9 billion energy research effort to tap the brightest minds in government, academia, and the private sector to tackle our energy problems through a portfolio of competitive research projects. One of the explicit purposes of this new research entity would be to speed commercialization of low-carbon energy technologies like those being pioneered at DayStar. The Strategic Energy Fund would put long-term incentives in place to accelerate the adoption of clean energy technologies. Specifically, the fund would provide a 10-year extension for the electricity production tax credit that applies to wind, solar and other renewables. Senator Clinton has also called for legislation to create a national renewable portfolio standard that would require 20% of our electricity to be generated from renewable sources by 2020. “We were honored and pleased that Senator Clinton asked to visit our facility, meet our staff, and view firsthand our Company’s leadership and progress towards commercializing our solar energy technologies,” said Dr. Tuttle. “It is clear that the Senator’s policies are aligned with Daystar’s mission of Gigawatt-scale manufacturing to achieve our vision of ‘Making Free Energy Affordable.’ We agree that the time is now to significantly increase investment in technologies such as ours that will help our nation regain its worldwide leadership in a sustainable energy future.” About DayStar Technologies, Inc. (NASDAQ: DSTI) DayStar Technologies, Inc. is an emerging leader in low cost, high efficiency Photovoltaic Foil™ that converts sunlight into energy. The Company manufactures CIGS solar cells, which are deposited on flexible metal foils using production processes adapted from the semiconductor and magnetic drive industries. As an alternative to wafer-silicon solar cells, DayStar believes the unique combination of its CIGS solar cell design coupled with proprietary manufacturing processes on flexible metal substrates could substantially lower costs and remove deployment barriers currently limiting large adoption of solar energy. For more information on the Company, please visit daystartech.com. SAFE HARBOR STATEMENT: This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future, " "plan" or "planned, " "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including risks that our products may not achieve customer acceptance or that they will not perform as expected, and other risks identified in our annual report on Form 10-KSB and other filings with the SEC. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof and DayStar Technologies Inc. undertakes no obligation to update such statements. FOR MEDIA RELATIONS INQUIRIES, PLEASE CONTACT Erica Dart, DayStar Technologies 518-383-4600 or via email edart@daystartech.com FOR INVESTOR RELATIONS INFORMATION, PLEASE CONTACT Dodi Handy, Elite Financial Communications Group 407-585-1080 or via email dsti@efcg.net ,